Welcome to our dedicated page for Orthofix Med news (Ticker: OFIX), a resource for investors and traders seeking the latest updates and insights on Orthofix Med stock.
Orthofix Medical Inc. (OFIX) is a global leader in orthopedic and spinal medical devices, delivering innovative solutions for bone repair and spinal treatments. This dedicated news hub provides investors and healthcare professionals with timely updates on corporate developments, clinical advancements, and regulatory milestones.
Access comprehensive coverage of OFIX's latest press releases, earnings reports, and strategic initiatives. Track updates across key areas including spinal implant innovations, bone growth therapy research, and global partnership announcements. Our curated news collection serves as an essential resource for understanding market positioning and operational progress.
Stay informed about critical developments in Orthofix's core segments: Global Spine solutions addressing complex spinal disorders and Global Orthopedics technologies for fracture repair. The page aggregates verified updates on product launches, clinical trial outcomes, and regulatory approvals – all vital for assessing the company's trajectory.
Bookmark this page for streamlined access to OFIX's evolving story. Combine fundamental analysis with real-time updates to make informed decisions about this innovative medical device pioneer.
Orthofix Medical Inc. (NASDAQ:OFIX) reported its Q1 2025 financial results with net sales of $193.6 million, representing a 2.7% increase year-over-year. The company posted a net loss of $(53.1) million, or $(1.35) per share. Notable performance includes Bone Growth Therapies sales growth of 5%, Global Orthopedics achieving 11% constant currency growth, and U.S. Spine Fixation growth of 4%.
The company updated its 2025 guidance, now expecting net sales between $808-816 million, while reaffirming non-GAAP adjusted EBITDA guidance of $82-86 million. Pro forma adjusted EBITDA for Q1 was $11.4 million, showing a 200 basis points margin expansion. The company is executing a commercial channel optimization strategy, though this has caused some softness in Biologics and Spine Fixation segments.
Cash position stood at $60.5 million as of March 31, 2025, down from $85.7 million in December 2024, primarily due to annual bonus payments and commissions.Orthofix Medical (NASDAQ:OFIX) has scheduled the release of its first quarter 2025 financial results for Tuesday, May 6, 2025, before the market opens. The company will host a conference call and webcast at 8:30 am Eastern Time on the same day to discuss the results.
Participants can join the conference call by dialing (888) 596-4144 in the U.S. and (646) 968-2525 from other locations, using conference ID 7524113. The webcast and earnings release will be available at ir.Orthofix.com.
Orthofix Medical Inc. (NASDAQ:OFIX) has received both FDA 510(k) clearance and European CE Mark for its TrueLok™ Elevate Transverse Bone Transport (TBT) System, marking a significant advancement in limb preservation treatment.
The system, currently in market release in the U.S. and select international markets, addresses bony and soft tissue deformities, including diabetic foot ulcers and nonhealing wounds. It is the first FDA-cleared dedicated system for TBT procedures, enabling surgeons to create and gradually distract bone segments in the tibia.
This innovation targets a $1.2 billion market opportunity, addressing the over 160,000 annual diabetic-related amputations in the U.S. Studies show patients with diabetic foot ulcers who undergo amputation face a 57% five-year mortality rate and lifetime healthcare costs exceeding $640,000 for amputation-related care.
Orthofix Medical (NASDAQ:OFIX) has appointed Vickie Capps to its Board of Directors, effective March 11, 2025. This strategic addition expands the board to ten members, bringing diverse expertise in global business operations, strategic development, and corporate finance.
Capps, a Certified Public Accountant with a B.S. in business administration from San Diego State University, brings significant experience from her role as former CFO of DJO Global, Inc. She currently serves on multiple boards, including Amedisys, Inc., Janux Therapeutics, Inc., Enable Injections, Inc., and Breg, Inc. She is also a member of the Senior Advisory Board of Consonance Capital Partners.
The appointment aligns with Orthofix's strategic transformation aimed at delivering profitable growth and sustainable shareholder value in the medical technology sector, focusing on musculoskeletal pathologies.
Orthofix Medical (NASDAQ:OFIX) has announced its participation in the 37th Annual Roth Conference in Dana Point, CA. The company's management team is scheduled to deliver a presentation on Monday, March 17, 2025, at 8:00 AM Pacific Time.
Investors and interested parties can access both the live and archived versions of the presentation through the 'Events & Presentations' section on Orthofix's investor relations website at ir.orthofix.com. The company also maintains regular updates of important investor information in the 'Investors' section of their corporate website at www.orthofix.com.
Orthofix Medical reported record fourth quarter 2024 net sales of $215.7 million, an 8% increase from Q4 2023. U.S. Spine Fixation sales grew by 12%, and Bone Growth Therapies (BGT) sales hit a record $63.9 million, a 9% increase. Global Orthopedics sales rose by 18% to $35.8 million. Despite these gains, the company reported a net loss of $(29.1) million and EPS of $(0.75). Non-GAAP adjusted EBITDA was $23.9 million, up 22% from Q4 2023. For the full year 2024, net sales reached $799.5 million, a 7% increase, with a net loss of $(126.0) million and EPS of $(3.30). Non-GAAP adjusted EBITDA for the year was $67.4 million, a 46% increase. Orthofix discontinued its M6 artificial disc product lines to focus on more profitable growth areas. The company provided 2025 guidance, expecting net sales between $818 million to $826 million and adjusted EBITDA between $82 million to $86 million. Free cash flow is expected to be positive for 2025.
Orthofix Medical (NASDAQ:OFIX) has announced its participation in the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego. The company's management will deliver a presentation on Monday, March 10, 2025, at 9:00 AM Pacific Time.
Investors and interested parties can access both the live and archived versions of the presentation through the 'Events & Presentations' section on Orthofix's investor relations website at ir.orthofix.com. The company regularly posts important investor information on its website www.orthofix.com under the 'Investors' section, and encourages current and potential investors to monitor this platform for updates.
Orthofix Medical (NASDAQ:OFIX) has scheduled the release of its fourth quarter and full-year 2024 financial results for Tuesday, February 25, 2025, before the market opens. The company will host a conference call and webcast at 8:30 am Eastern Time on the same day to discuss the results.
Participants can join the conference call by dialing (888) 596-4144 in the U.S. and (646) 968-2525 from other locations, using the event passcode 5184023. The webcast and earnings release will be available on the company's investor relations website at ir.Orthofix.com.
Orthofix Medical (NASDAQ:OFIX) has announced its leadership team's participation in two upcoming investor conferences. President and CEO Massimo Calafiore and CFO Julie Andrews will attend the Stifel 2024 Healthcare Conference in New York on November 18, 2024, with a fireside chat at 8:35 AM ET, and the Stifel MedTech Madness 2024 Annual West Coast Bus Tour in Laguna Beach on December 9, 2024, with a fireside chat at 8:00 AM PT. Live webcasts and replays will be available on the Orthofix website's Investors section.
Orthofix Medical (NASDAQ:OFIX) has secured a new $275 million senior-secured term loan with Oxford Finance , featuring a 48-month interest-only period. The initial $160 million will retire existing credit facilities, while the remaining $115 million will be available after January 2025. Of this amount, $65 million will be accessible at borrower's option through June 2026, and $50 million at lender's discretion through January 2029. The company reports significant improvements in adjusted EBITDA and achieving free cash flow positive status in 2024, supporting their strategy for long-term profitable growth.
FAQ
What is the current stock price of Orthofix Med (OFIX)?
What is the market cap of Orthofix Med (OFIX)?
